Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SynKIR-310 by Verismo Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval
SynKIR-310 is under clinical development by Verismo Therapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
Data Insights
SynKIR-310 by Verismo Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
SynKIR-310 is under clinical development by Verismo Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...